Gadodiamide

Evidence Level: L5

Predicted Indications: 1

Gadodiamide

Pharmacist Assessment Report

Gadodiamide: From a Diagnostic MRI Contrast Agent to Rheumatoid Arthritis

One-Sentence Summary

Gadodiamide is a gadolinium-based contrast agent used in magnetic resonance imaging (MRI), marketed in Canada as OMNISCAN. The TxGNN model predicts it may be associated with rheumatoid arthritis, but there are no registered clinical trials and only 3 publications, all of which used gadodiamide as an imaging tool rather than as a treatment.

Quick Overview

Item	Content
Original Indication	Not specified in the available licence data (gadodiamide is a diagnostic MRI contrast agent)
Predicted New Indication	Rheumatoid arthritis
TxGNN Prediction Score	0.9916
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, gadodiamide is a gadolinium-based contrast agent. It enhances MRI images and has no recognised therapeutic anti-inflammatory activity.

The three publications found (2001–2002) used gadodiamide-enhanced MRI to visualize synovitis, bone marrow edema and bone erosions in patients with rheumatoid arthritis and other inflammatory joint diseases. This is a diagnostic use, not a therapeutic one. The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. At present there is no sound mechanistic reason to consider gadodiamide a treatment for rheumatoid arthritis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11669155	2001	Cohort	The Journal of Rheumatology	MRI features of wrist and finger joints compared across early RA, established RA, other arthritis and arthralgia
11976868	2002	Cohort	European Radiology	In 84 patients, MRI synovial volume and bone marrow oedema were assessed for predicting bone erosion progression at 1 year
11419149	2001	Cohort	European Radiology	Compared low-field extremity MRI (0.2 T) with high-field MRI (1.5 T) in 103 patients with arthritic small joints

All three studies concern diagnostic imaging, not treatment.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02172771	OMNISCAN	Not specified	Not specified

Safety Considerations

Drug Interactions: The data compiled for this report list 100 potential interacting drugs, almost all with an unclassified severity level. The only one with a graded severity is acebutolol (Moderate). Others with unclassified severity include calcitriol, pantoprazole, omeprazole, lansoprazole, vancomycin, prednisone, simvastatin, potassium chloride, dexamethasone and acetylsalicylic acid.

Please refer to the package insert for other safety information, including warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The supporting literature describes gadodiamide as an imaging agent, not a therapy, and there are no clinical trials. No therapeutic mechanism is known.

To proceed, the following is needed:

Mechanism of action data showing a plausible therapeutic pathway
Health Canada package insert warnings and contraindications, needed for any safety screening
Approved indication and dosage form details for the Canadian licence
Preclinical or clinical evidence of a therapeutic effect, not just diagnostic use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.